Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure
Arq Bras Cardiol. 2016 Feb;106(2):145-52.
doi: 10.5935/abc.20150151.
Epub 2016 Jan 15.
[Article in
English,
Portuguese]
Affiliations
- 1 Universidade Federal Fluminense, Niterói, RJ, Brazil.
- 2 Division of Cardiovascular Medicine, University of California, San Diego, United States.
Abstract
ST2 is a member of the interleukin-1 receptor family biomarker and circulating soluble ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Recent studies have demonstrated soluble ST2 to be a strong predictor of cardiovascular outcomes in both chronic and acute heart failure. It is a new biomarker that meets all required criteria for a useful biomarker. Of note, it adds information to natriuretic peptides (NPs) and some studies have shown it is even superior in terms of risk stratification. Since the introduction of NPs, this has been the most promising biomarker in the field of heart failure and might be particularly useful as therapy guide.
MeSH terms
-
Biomarkers / blood
-
Disease Management
-
Heart Failure / blood*
-
Heart Failure / physiopathology
-
Heart Failure / therapy*
-
Humans
-
Interleukin-1 Receptor-Like 1 Protein
-
Prognosis
-
Receptors, Cell Surface / blood*
-
Reference Values
-
Risk Assessment / methods
-
Solubility
-
Time Factors
Substances
-
Biomarkers
-
IL1RL1 protein, human
-
Interleukin-1 Receptor-Like 1 Protein
-
Receptors, Cell Surface